Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...
KAMR Amarillo on MSN2d
ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinomaThomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback